These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 1222395)

  • 1. Phase I-II evaluation of emetine (NSC-33669) in the treatment of epidermoid bronchogenic carcinoma.
    Kane RC; Cohen MH; Broder LE; Bull MI; Creaven PJ; Fossieck BE
    Cancer Chemother Rep; 1975; 59(6):1171-2. PubMed ID: 1222395
    [No Abstract]   [Full Text] [Related]  

  • 2. Cyclophosphamide plus emetine in lung cancer.
    Street EW
    Lancet; 1972 Aug; 2(7773):381-2. PubMed ID: 4114753
    [No Abstract]   [Full Text] [Related]  

  • 3. Experience with emetine hydrochloride (NSC 33669) as an antitumor agent.
    Panettiere F; Coltman CA
    Cancer; 1971 Apr; 27(4):835-41. PubMed ID: 4929936
    [No Abstract]   [Full Text] [Related]  

  • 4. Cyclophosphamide plus emetine in lung cancer.
    Hyde KR; Marsh K; Perry W
    Lancet; 1972 Aug; 2(7774):427. PubMed ID: 4115244
    [No Abstract]   [Full Text] [Related]  

  • 5. Phase II study of the effect of methyl-CCNU (NSC-95441) on bronchogenic carcinoma.
    Takita H; Brugarolas A; Mittelman A; Vincent R
    Cancer Chemother Rep 3; 1973 Mar; 4(2):257-9. PubMed ID: 4125743
    [No Abstract]   [Full Text] [Related]  

  • 6. Combination chemotherapy of bronchogenic carcinoma with cyclophosphamide (NSC-26271) and BCNU (NSC-409962).
    Curtis JE
    Cancer Chemother Rep; 1974; 58(6):883-8. PubMed ID: 4614897
    [No Abstract]   [Full Text] [Related]  

  • 7. Vincristine (NSC 67574) in non-small cell bronchogenic carcinoma. Results of a phase II clinical study.
    Brugarolas A; Lacave AJ; Ribas A; Miralles MT
    Eur J Cancer (1965); 1978 May; 14(5):501-5. PubMed ID: 348479
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase II evaluation of vindesine in non-small cell bronchogenic carcinoma.
    Hutcheon AW; Palmer JB; Pratt MA; Clark RA
    Cancer Treat Rep; 1983 Nov; 67(11):1041-2. PubMed ID: 6315231
    [No Abstract]   [Full Text] [Related]  

  • 9. Radiation plus 5-fluorouracil (NSC-19893): clinical demonstration of an additive effect in bronchogenic carcinoma.
    Cohen JL; Krant MJ; Shnider BI; Matias PI; Horton J; Baxter D
    Cancer Chemother Rep; 1971 Jun; 55(3):253-8. PubMed ID: 5115846
    [No Abstract]   [Full Text] [Related]  

  • 10. An evaluation of combination chemotherapy with procarbazine (NSC-77213) and 5-fluorouracil (NSC-19893) in advanced carcinoma of the lung.
    Gottlieb JA; Serpick AA
    Cancer Chemother Rep; 1970 Oct; 54(5):369-71. PubMed ID: 5514626
    [No Abstract]   [Full Text] [Related]  

  • 11. [Does chemotherapy bring real benefit to patients with inoperable bronchial epidermoid cancer?].
    Depierre A
    Rev Mal Respir; 1986; 3(4):169-71. PubMed ID: 3786923
    [No Abstract]   [Full Text] [Related]  

  • 12. [Selective bronchial artery perfusion with cisplatin in the treatment of inoperable bronchogenic carcinoma].
    Liu ZJ
    Zhonghua Fang She Xue Za Zhi; 1987 Feb; 21(1):4-7. PubMed ID: 2954790
    [No Abstract]   [Full Text] [Related]  

  • 13. Cyclophosphamide (NSC-26271) as adjuvant to radiotherapy in the treatment of unresectable bronchogenic carcinoma.
    Host H
    Cancer Chemother Rep 3; 1973 Mar; 4(2):161-4. PubMed ID: 4729319
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of long-term adjuvant chemotherapy with cyclophosphamide (NSC-26271) for radically resected bronchogenic carcinoma.
    Brunner KW; Marthaler T; Müller W
    Cancer Chemother Rep 3; 1973 Mar; 4(2):125-32. PubMed ID: 4199643
    [No Abstract]   [Full Text] [Related]  

  • 15. [Intra-arterial drug infusion via the bronchial artery in the treatment of bronchogenic carcinoma].
    Wang ZT
    Zhonghua Fang She Xue Za Zhi; 1988 Aug; 22(4):216-9. PubMed ID: 3145173
    [No Abstract]   [Full Text] [Related]  

  • 16. Bronchial arterial perfusion with cytotoxic agents for bronchogenic carcinoma. Preliminary report.
    Tate CF; Viamonte M; Agnew JR
    Am Rev Respir Dis; 1968 Apr; 97(4):685-93. PubMed ID: 4296229
    [No Abstract]   [Full Text] [Related]  

  • 17. Cytostatic infusion into bronchial arteries in bronchogenic carcinoma.
    Ekholm S; Albrechtsson U; Hellekant C; Jonsson K; Nyman U; Tylén U
    Ann Radiol (Paris); 1980; 23(4):346-8. PubMed ID: 7387096
    [No Abstract]   [Full Text] [Related]  

  • 18. Hexamethylmelamine in inoperable bronchogenic carcinoma.
    Takita H
    N Y State J Med; 1972 Feb; 72(4):477-80. PubMed ID: 4334448
    [No Abstract]   [Full Text] [Related]  

  • 19. [Experience of photodynamic therapy in inoperable bronchogenic cancer in the city of Nancy. Apropos of 3 cases].
    Feintrenie X; Lignon D; Arboit F; Ménard O; Jonveaux E; Martinet Y; Guillemin F
    Rev Pneumol Clin; 1992; 48(3):129-30. PubMed ID: 1439465
    [No Abstract]   [Full Text] [Related]  

  • 20. Aclacinomycin A. Phase II evaluation in bronchogenic squamous-cell carcinoma.
    Pazdur R; Samson MK; Baker LH
    Am J Clin Oncol; 1987 Jun; 10(3):234-6. PubMed ID: 3473923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.